CLL session starts at 4:34 pm on September 4
We have very good speakers and some really interesting topics at this year’s CLL session. The session opens with Dr. Lydia Scarfò’s presentation
Leukemia News
SOHO 2025
Meetings / Conferences
News
MPN News
MDS News
Lymphoma News
Leukemia News
Multiple Myeloma News
SOHO 2025
News
Dr. Garcia-Manero wins 1st place for abstracts
The Society of Hematologic Oncology (SOHO) announced the abstract award winners of its 13th Annual Meeting at Wednesday evening’s award ceremony, presenting eight
MPN News
SOHO 2025
Gabriela Hobbs, MD, previews the 8 am MPN session on September 4
The myeloproliferative neoplasms (MPNs) session this morning will bring together a full spectrum of timely topics, from novel therapies in polycythemia vera (PV)
MDS News
SOHO 2025
Hematologic oncology enters a transformative period
These are truly transformative times in the field of hematologic malignancies. Diseases that were once considered untreatable are now being managed—and in some
Leukemia News
SOHO 2025
News
Don’t miss: AML session starts at 3:51 pm on September 3
Andrew Wei, MBBS, PhD, previews this year’s AML session starting at 3:51 pm today, September 3
Society Updates
SOHO reaches 10,000-member milestone
SOHO is excited to announce that we are now more than 10,000 members strong! Our members span the globe, and we thank them
SOHO 2025
Meeting News
SOHO 2025 program book available now
The Society of Hematologic Oncology has released the SOHO 2025 program book, detailing the Thirteenth Annual Meeting, set for September 3–6, 2025, at
SBBC
SOHO 2025
Meetings / Conferences
Society Updates
Building on a solid foundation to impact the future
In September 2012, the Society of Hematologic Oncology (SOHO) began with just 400 members and a vision to bring the knowledge of the
News
SOHO Insider Podcast
Drs. Kuykendall and Gerds discuss myelofibrosis anemia challenges
I put anemia near the top of the list, or at least an equal footing with spleen and symptoms,” Dr. Gerds said.
Leukemia
Chronic Lymphocytic Leukemia
Birelentinib granted Fast Track designation by FDA for CLL/SLL
The US Food and Drug Administration granted Fast Track Designation to birelentinib (DZD8586), a first-in-class lymphocyte-specific protein tyrosine kinase/Bruton’s tyrosine kinase (LYN/BTK) dual